Ryan Fukushima Sells 2,868 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 2,868 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $81.87, for a total transaction of $234,803.16. Following the sale, the chief operating officer now directly owns 944,460 shares in the company, valued at approximately $77,322,940.20. This represents a 0.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $62.50, for a total transaction of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Trading Down 10.5 %

Shares of TEM stock opened at $76.72 on Friday. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a 50 day moving average price of $49.75 and a 200 day moving average price of $51.44.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. ARK Investment Management LLC increased its position in Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after purchasing an additional 3,141,487 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Nikko Asset Management Americas Inc. increased its position in Tempus AI by 166.0% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Franklin Resources Inc. increased its position in Tempus AI by 240.5% during the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock worth $93,251,000 after purchasing an additional 1,950,862 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Tempus AI by 86,947.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock worth $55,836,000 after purchasing an additional 1,651,996 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TEM shares. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.